US Cardiovascular Drugs Market Analysis Report 2022 to 2030

US Cardiovascular Drugs Market Analysis

$ 3999

US Cardiovascular Drug Market is at around $58.1 Bn in 2022 and is projected to reach $67.01 Bn in 2030, exhibiting a CAGR of 1.8% during the forecast period. The major reasons propelling the growth of this market are the increasing prevalence of chronic diseases, technological advancements, and the rise in government initiatives, among others. The market is dominated by key players like Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., Astra Zeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., and F. Hoffman-La Roche Ltd.

ID: IN10USPH007 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Aneri Parekh

Buy Now

US Cardiovascular Drug Market Executive Summary

US Cardiovascular Drug Market is at around $58.1 Bn in 2022 and is projected to reach $67.01 Bn in 2030, exhibiting a CAGR of 1.8% during the forecast period.

Heart attacks, strokes, and venous thromboembolism fall under cardiovascular diseases since they impact the cardiovascular system as well as the blood and lymphatic vessels. The primary cause of heart attacks and strokes, which are typically acute events, is a blockage that stops blood flow to the brain or heart. Patients with heart conditions ought to have access to the right drugs and technologies. Aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and statins are examples of basic medications that ought to be accessible to patients.

The rising frequency of cardiovascular illness is fueling the steady rise of the US cardiovascular drug market. Market growth is aided by pharmaceutical developments, especially in the areas of anticoagulants and antihypertensives. The realities of the competitive landscape require that major firms concentrate on R&D for novel treatments and tactical alliances to keep their market leadership.

Pharma revenues increased dramatically over the preceding two decades, reaching $138.33 Bn globally in 2022. The pharmaceutical sector has seen a dramatic shift with the advent of new technology and more affordable and efficient manufacturing methods. In addition, the increasing flow of investments in this industry has contributed positively to the market's growth.

Bristol-Myers Squibb’s primary cardiovascular medications are the anticoagulant Eliquis, the antiplatelet medicine Apixaban, and the mTOR inhibitor Relion/Afinitor, which is used to treat heart failure. Despite some general rivalry in some markets, these contribute significantly to their revenue.

Market Dynamics

Market Growth Drivers:

Increasing Prevalence of Cardiac Arrhythmias: Market growth is driven by the rising prevalence of cardiovascular diseases. It takes one life every 33 seconds. In 2021, approximately 0.7 Mn people died of heart disease.

Frequent Product Approvals: Market expansion is aided by frequent product approvals. In 2022, the FDA increased the use of empagliflozin (Jardiance).

Prevalence of Hypertension: The market for cardiovascular medications is boosted by the increased risk of cardiovascular illnesses brought about by the high incidence of hypertension among the population. The incidence of cardiovascular problems has grown among young people from emerging countries due to their extended work hours.

Market Restraints:

Strict Regulatory Process: Market growth is restricted by stringent regulatory processes such as lengthy approval procedures and dynamic safety criteria, which may delay the prompt launch of novel cardiovascular medications.

High Cost of Pharmaceuticals: The rising cost of pharmaceuticals can hamper the growth of the cardiovascular drug market in the US.

Expiration of Patents: Entry of generic alternatives into the market and the expiration of patents for important cardiovascular medications is the potential erosion of pharmaceutical companies' revenue due to increasing competition.

Notable Recent Updates

January 2023, following the patent expiration of Novartis's heart drug Sacubitril and Valsartan, Lupin Pharmaceuticals, a global player in drug discovery, launched the generic version of the combination drug. It will be marketed under two brand names, Valentas and Arnipin, and is intended for patients with heart failure

Healthcare Policies and Regulatory Landscape

Food and Drug Administration is the regulatory agency in charge of regulating cardiovascular medications in the US (FDA). The FDA is in charge of assessing and approving new medications, guaranteeing their efficacy. For the majority of novel therapeutic medications and biologics, the development process consists of three main stages: pre-clinical, clinical, and FDA review. Getting a license for cardiovascular medication is a challenging procedure that comes with a lot of obstacles like strict regulations, protracted and expensive development timelines, and clinical trial challenges.

Competitive Landscape

Key Players:

Bristol-Myers Squibb Company
Pfizer Inc.
Bayer AG
Janssen Pharmaceuticals, Inc.
Astra Zeneca
Sanofi
Novartis AG
Merck & Co., Inc.
Gilead Sciences, Inc.
F. Hoffmann-La Roche Ltd

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Cardiovascular Drug Market Segmentation

By Drug Type

Cephalosporins
Antihypertensive
Antihyperlipidemic
Anticoagulants
Antiplatelet Drug
Other

By Disease Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Arrhythmia
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.